“SPOT IT, STOP IT”: A Mission to Fight Cancer through Early Detection

Imagine if we could find cancer early, before it spreads and becomes harder to treat. In the Philippines, cancer is the 2nd the leading cause of death in the country, and common types like breast, lung, colorectal, and liver cancers impact countless lives. (1)(2)

For 2024, the numbers are clear. Breast cancer is the most common cancer among Filipinas, making up nearly 17.5% cancer cases (3). For Filipino men, lung cancer is the most common, accounting for 12.6% of cases (3). Colorectal and liver cancers also claim many lives, with each making up 11.0% and 6.6% of cases, respectively (3). These numbers underscore a critical and urgent need for regular check-ups and early detection.

To address this, Gene Solutions Philippines and The Medical City (TMC) have launched the “Spot It, Stop It” campaign. The campaign, with its slogan “SPOT IT, STOP IT,” is a reminder that we can take control of our health. By spotting cancer early, we have a better chance of stopping it and improving quality of life for patients.

Running from August 19 to September 30, 2024, this initiative aims to empower people to detect cancer early through advanced SPOTMAS screening tests and exclusively for TMC employees will get 35% discounts.

What is SPOTMAS?

SPOTMAS is a multi-cancer early screening for asymptomatic patients, utilizing next generation sequencing to detect the presence and location of most common cancer in Southeast Asia.

The test is available in three versions:

  • SPOTMAS 5: to detect the presence and location of five most common cancer – Liver, Breast, Lung, Colorectal and Stomach.
  • SPOTMAS 10: to detect the presence and location in addition to five aggressive cancer types – Uterus, Esophagus, Ovary, Pancreas and Biliary Tract. These cancer types are notably do not have recommended screening methods yet.
  • SPOTMAS 360: in addition to 10 cancer types of detection, this test also analyzes the risks of 32 inherited cancer types, cardiovascular genes relating to sudden death.

These tests help to detect cancer at its earliest stages, giving you and your loved ones the best chance at successful treatment. The “Spot It, Stop It” campaign is more than a call for screenings—it’s a movement. A movement to raise awareness, encourage early detection, and provide hope.

Together, we can spot cancer early and stop it in its tracks.

 

(1) International Agency for Research on Cancer. Global Cancer Observatory; 2020. Philippines Population Fact Sheet.https://gco.iarc.fr/today/data/factsheets/populations/608-philippines-fact-sheets.pdf [internet] [cited 2022 Apr 13].  (link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971506/ & https://www.themedicalcity.com/news/cancer)

(2) Ho, F. D. V., Arevalo, M. V. P. N., De Claro, P. T. S., Jacomina, L. E., Germar, M. J. V., Dee, E. C., & Eala, M. a. B. (2022). Breast and cervical cancer screening in the Philippines: Challenges and steps forward. Preventive Medicine Reports, 29, 101936. https://doi.org/10.1016/j.pmedr.2022.101936 

(3) GLOBOCAN Indonesia (2022)  

(4) American Cancer Society Guidelines (2023) 

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More